Cargando…
Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study
BACKGROUND: Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523984/ https://www.ncbi.nlm.nih.gov/pubmed/23107021 http://dx.doi.org/10.1186/1475-2875-11-356 |
_version_ | 1782253254209437696 |
---|---|
author | Talisuna, Ambrose O Daumerie, Penny Grewal Balyeku, Andrew Egan, Timothy Piot, Bram Coghlan, Renia Lugand, Maud Bwire, Godfrey Rwakimari, John Bosco Ndyomugyenyi, Richard Kato, Fred Byangire, Maria Kagwa, Paul Sebisubi, Fred Nahamya, David Bonabana, Angela Mpanga-Mukasa, Susan Buyungo, Peter Lukwago, Julius Batte, Allan Nakanwagi, Grace Tibenderana, James Nayer, Kinny Reddy, Kishore Dokwal, Nilesh Rugumambaju, Sylvester Kidde, Saul Banerji, Jaya Jagoe, George |
author_facet | Talisuna, Ambrose O Daumerie, Penny Grewal Balyeku, Andrew Egan, Timothy Piot, Bram Coghlan, Renia Lugand, Maud Bwire, Godfrey Rwakimari, John Bosco Ndyomugyenyi, Richard Kato, Fred Byangire, Maria Kagwa, Paul Sebisubi, Fred Nahamya, David Bonabana, Angela Mpanga-Mukasa, Susan Buyungo, Peter Lukwago, Julius Batte, Allan Nakanwagi, Grace Tibenderana, James Nayer, Kinny Reddy, Kishore Dokwal, Nilesh Rugumambaju, Sylvester Kidde, Saul Banerji, Jaya Jagoe, George |
author_sort | Talisuna, Ambrose O |
collection | PubMed |
description | BACKGROUND: Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy. METHODS: Four intervention districts were purposefully selected to receive branded subsidized medicines - “ACT with a leaf”, while the fifth district acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at licensed and unlicensed drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention’s impact on: ACT uptake and price; purchase of ACT within 24 hours of symptom onset; ACT availability and displacement of sub-optimal anti-malarial. RESULTS: At baseline, ACT accounted for less than 1% of anti-malarials purchased from licensed drug shops for children less than five years old. However, at evaluation, “ACT with a leaf” accounted for 69% of anti-malarial purchased in the interventions districts. Purchase of ACT within 24 hours of symptom onset for children under five years rose from 0.8% at baseline to 26.2% (95% CI: 23.2-29.2%) at evaluation in the intervention districts. In the control district, it rose modestly from 1.8% to 5.6% (95% CI: 4.0-7.3%). The odds of purchasing ACT within 24 hours in the intervention districts compared to the control was 0.46 (95% CI: 0.08-2.68, p=0.4) at baseline and significant increased to 6.11 (95% CI: 4.32-8.62, p<0.0001) at evaluation. Children less than five years of age had “ACT with a leaf” purchased for them more often than those aged above five years. There was no evidence of price gouging. CONCLUSIONS: These data demonstrate that a supply-side subsidy and an intensive communications campaign significantly increased the uptake and use of ACT in the private sector in Uganda. |
format | Online Article Text |
id | pubmed-3523984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35239842012-12-18 Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study Talisuna, Ambrose O Daumerie, Penny Grewal Balyeku, Andrew Egan, Timothy Piot, Bram Coghlan, Renia Lugand, Maud Bwire, Godfrey Rwakimari, John Bosco Ndyomugyenyi, Richard Kato, Fred Byangire, Maria Kagwa, Paul Sebisubi, Fred Nahamya, David Bonabana, Angela Mpanga-Mukasa, Susan Buyungo, Peter Lukwago, Julius Batte, Allan Nakanwagi, Grace Tibenderana, James Nayer, Kinny Reddy, Kishore Dokwal, Nilesh Rugumambaju, Sylvester Kidde, Saul Banerji, Jaya Jagoe, George Malar J Research BACKGROUND: Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy. METHODS: Four intervention districts were purposefully selected to receive branded subsidized medicines - “ACT with a leaf”, while the fifth district acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at licensed and unlicensed drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention’s impact on: ACT uptake and price; purchase of ACT within 24 hours of symptom onset; ACT availability and displacement of sub-optimal anti-malarial. RESULTS: At baseline, ACT accounted for less than 1% of anti-malarials purchased from licensed drug shops for children less than five years old. However, at evaluation, “ACT with a leaf” accounted for 69% of anti-malarial purchased in the interventions districts. Purchase of ACT within 24 hours of symptom onset for children under five years rose from 0.8% at baseline to 26.2% (95% CI: 23.2-29.2%) at evaluation in the intervention districts. In the control district, it rose modestly from 1.8% to 5.6% (95% CI: 4.0-7.3%). The odds of purchasing ACT within 24 hours in the intervention districts compared to the control was 0.46 (95% CI: 0.08-2.68, p=0.4) at baseline and significant increased to 6.11 (95% CI: 4.32-8.62, p<0.0001) at evaluation. Children less than five years of age had “ACT with a leaf” purchased for them more often than those aged above five years. There was no evidence of price gouging. CONCLUSIONS: These data demonstrate that a supply-side subsidy and an intensive communications campaign significantly increased the uptake and use of ACT in the private sector in Uganda. BioMed Central 2012-10-29 /pmc/articles/PMC3523984/ /pubmed/23107021 http://dx.doi.org/10.1186/1475-2875-11-356 Text en Copyright ©2012 Talisuna et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Talisuna, Ambrose O Daumerie, Penny Grewal Balyeku, Andrew Egan, Timothy Piot, Bram Coghlan, Renia Lugand, Maud Bwire, Godfrey Rwakimari, John Bosco Ndyomugyenyi, Richard Kato, Fred Byangire, Maria Kagwa, Paul Sebisubi, Fred Nahamya, David Bonabana, Angela Mpanga-Mukasa, Susan Buyungo, Peter Lukwago, Julius Batte, Allan Nakanwagi, Grace Tibenderana, James Nayer, Kinny Reddy, Kishore Dokwal, Nilesh Rugumambaju, Sylvester Kidde, Saul Banerji, Jaya Jagoe, George Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study |
title | Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study |
title_full | Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study |
title_fullStr | Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study |
title_full_unstemmed | Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study |
title_short | Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study |
title_sort | closing the access barrier for effective anti-malarials in the private sector in rural uganda: consortium for act private sector subsidy (capss) pilot study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523984/ https://www.ncbi.nlm.nih.gov/pubmed/23107021 http://dx.doi.org/10.1186/1475-2875-11-356 |
work_keys_str_mv | AT talisunaambroseo closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT daumeriepennygrewal closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT balyekuandrew closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT egantimothy closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT piotbram closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT coghlanrenia closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT lugandmaud closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT bwiregodfrey closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT rwakimarijohnbosco closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT ndyomugyenyirichard closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT katofred closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT byangiremaria closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT kagwapaul closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT sebisubifred closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT nahamyadavid closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT bonabanaangela closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT mpangamukasasusan closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT buyungopeter closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT lukwagojulius closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT batteallan closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT nakanwagigrace closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT tibenderanajames closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT nayerkinny closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT reddykishore closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT dokwalnilesh closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT rugumambajusylvester closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT kiddesaul closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT banerjijaya closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy AT jagoegeorge closingtheaccessbarrierforeffectiveantimalarialsintheprivatesectorinruralugandaconsortiumforactprivatesectorsubsidycapsspilotstudy |